Form 4: Centessa Pharmaceuticals Executive Acquires 500,000 Share Options

Stephen Kanes, Chief Medical Officer of Centessa Pharmaceuticals, reports the acquisition of 500,000 share options on February 3, 2025.

Summary

• Stephen Kanes, the Chief Medical Officer of Centessa Pharmaceuticals plc, filed a Form 4 on February 4, 2025, reporting changes in beneficial ownership.
• The report indicates that Kanes acquired 500,000 share options on February 3, 2025, with an exercise price of $16.90.
• These options vest over time, with 25% becoming exercisable on February 3, 2026, and the remaining 75% vesting in 36 monthly installments thereafter.
• The options expire on February 3, 2035.
• The underlying security for these options are ordinary shares, which may be represented by American Depositary Shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of share options by an executive could be seen as a mildly positive sign, indicating confidence in the company's future.

Positives

• The acquisition of share options by a key executive could be interpreted as a sign of confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the acquisition of share options, which is a common form of executive compensation in the pharmaceutical industry.

Stakeholder Impact

• The acquisition of share options by a key executive could have a minor positive impact on shareholder sentiment.

Key Dates